1477 — Ocumension Therapeutics Balance Sheet
0.000.00%
- HK$6.38bn
- HK$5.84bn
- CNY417.31m
- 14
- 14
- 80
- 25
Annual balance sheet for Ocumension Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,052 | 1,785 | 1,314 | 1,054 | 769 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 48.6 | 44.4 | 113 | 119 | 164 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,103 | 1,835 | 1,455 | 1,206 | 979 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 82 | 366 | 448 | 468 | 452 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,600 | 3,331 | 3,044 | 3,271 | 3,974 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 91.9 | 216 | 248 | 315 | 155 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 97.2 | 223 | 295 | 351 | 200 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 2,502 | 3,108 | 2,749 | 2,920 | 3,774 |
| Total Liabilities & Shareholders' Equity | 2,600 | 3,331 | 3,044 | 3,271 | 3,974 |
| Total Common Shares Outstanding |